ALT5 Sigma (NASDAQ:ALTS) Issues Earnings Results

ALT5 Sigma (NASDAQ:ALTS) issued its quarterly earnings data on Monday. The company reported $0.29 earnings per share for the quarter, FiscalAI reports. ALT5 Sigma had a negative net margin of 74.89% and a negative return on equity of 179.27%. The company had revenue of $7.58 million for the quarter.

ALT5 Sigma Stock Performance

Shares of ALT5 Sigma stock opened at $1.61 on Tuesday. ALT5 Sigma has a 1-year low of $1.08 and a 1-year high of $10.95. The company’s fifty day simple moving average is $1.59 and its 200-day simple moving average is $3.89. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 1.45.

Hedge Funds Weigh In On ALT5 Sigma

Institutional investors have recently bought and sold shares of the stock. Evernest Financial Advisors LLC bought a new stake in ALT5 Sigma during the second quarter valued at about $87,000. Geode Capital Management LLC lifted its position in shares of ALT5 Sigma by 27.6% during the 2nd quarter. Geode Capital Management LLC now owns 194,813 shares of the company’s stock valued at $1,412,000 after buying an additional 42,157 shares in the last quarter. Jane Street Group LLC bought a new position in shares of ALT5 Sigma during the 2nd quarter valued at approximately $380,000. Bridgeway Capital Management LLC increased its holdings in ALT5 Sigma by 9.4% in the 2nd quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company’s stock worth $140,000 after acquiring an additional 1,661 shares in the last quarter. Finally, Arkadios Wealth Advisors purchased a new stake in ALT5 Sigma in the 3rd quarter worth approximately $62,000. 6.27% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of ALT5 Sigma in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.